Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial f…
Biotechnology
US, Redwood City [HQ]
Investor Relations
Filing Reader · Print Documents · Transcripts
Could not find a transcript
Peer Group
Peers Analysis-
Sorry! None of RVMD's peers has listed transcripts.
Upcoming Transcript Tools
- Full Text Search - Across All Transcripts
- Detail Speaker Profiles
- Non-US Transcripts